Next Article in Journal
Synthesis of Elaborate Benzofuran-2-Carboxamide Derivatives through a Combination of 8-Aminoquinoline Directed C–H Arylation and Transamidation Chemistry
Next Article in Special Issue
Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type
Previous Article in Journal
Correlations Between Trace Elements in Selected Locations of the Human Brain in Individuals with Alcohol Use Disorder
Open AccessFeature PaperArticle

Design of Disruptors of the Hsp90–Cdc37 Interface

SCITEC-CNR, via Mario Bianco 9, 20131 Milan, Italy
Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv 6997801, Israel
Department of Chemistry, University of Pavia, via Taramelli 12, 27100 Pavia, Italy
Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, 20133 Milan, Italy
Department of Urology, SUNY Upstate Medical University Syracuse, Syracuse, NY 13210, USA
Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University Syracuse, Syracuse, NY 13210, USA
Upstate Cancer Center, SUNY Upstate Medical University Syracuse, Syracuse, NY 13210, USA
College of Medicine, SUNY Upstate Medical University Syracuse, Syracuse, NY 13210, USA
Authors to whom correspondence should be addressed.
Molecules 2020, 25(2), 360;
Received: 3 December 2019 / Revised: 8 January 2020 / Accepted: 13 January 2020 / Published: 15 January 2020
(This article belongs to the Special Issue Drug Discovery and Molecular Docking)
The molecular chaperone Hsp90 is a ubiquitous ATPase-directed protein responsible for the activation and structural stabilization of a large clientele of proteins. As such, Hsp90 has emerged as a suitable candidate for the treatment of a diverse set of diseases, such as cancer and neurodegeneration. The inhibition of the chaperone through ATP-competitive inhibitors, however, was shown to lead to undesirable side effects. One strategy to alleviate this problem is the development of molecules that are able to disrupt specific protein–protein interactions, thus modulating the activity of Hsp90 only in the particular cellular pathway that needs to be targeted. Here, we exploit novel computational and theoretical approaches to design a set of peptides that are able to bind Hsp90 and compete for its interaction with the co-chaperone Cdc37, which is found to be responsible for the promotion of cancer cell proliferation. In spite of their capability to disrupt the Hsp90–Cdc37 interaction, no important cytotoxicity was observed in human cancer cells exposed to designed compounds. These findings imply the need for further optimization of the compounds, which may lead to new ways of interfering with the Hsp90 mechanisms that are important for tumour growth. View Full-Text
Keywords: Hsp90; cdc37; protein–protein interaction; peptide design Hsp90; cdc37; protein–protein interaction; peptide design
Show Figures

Figure 1

MDPI and ACS Style

D’Annessa, I.; Hurwitz, N.; Pirota, V.; Beretta, G.L.; Tinelli, S.; Woodford, M.; Freccero, M.; Mollapour, M.; Zaffaroni, N.; Wolfson, H.; Colombo, G. Design of Disruptors of the Hsp90–Cdc37 Interface. Molecules 2020, 25, 360.

AMA Style

D’Annessa I, Hurwitz N, Pirota V, Beretta GL, Tinelli S, Woodford M, Freccero M, Mollapour M, Zaffaroni N, Wolfson H, Colombo G. Design of Disruptors of the Hsp90–Cdc37 Interface. Molecules. 2020; 25(2):360.

Chicago/Turabian Style

D’Annessa, Ilda; Hurwitz, Naama; Pirota, Valentina; Beretta, Giovanni L.; Tinelli, Stella; Woodford, Mark; Freccero, Mauro; Mollapour, Mehdi; Zaffaroni, Nadia; Wolfson, Haim; Colombo, Giorgio. 2020. "Design of Disruptors of the Hsp90–Cdc37 Interface" Molecules 25, no. 2: 360.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop